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miR-34a and miR-15a/16 are co-regulated in non-
small cell lung cancer and control cell cycle
progression in a synergistic and Rb-dependent
manner
Nora Bandi and Erik Vassella*
Abstract
Background: microRNAs (miRNAs) are small non-coding RNAs that are frequently involved in carcinogenesis.
Although many miRNAs form part of integrated networks, little information is available how they interact with
each other to control cellular processes. miR-34a and miR-15a/16 are functionally related; they share common
targets and control similar processes including G1-S cell cycle progression and apoptosis. The aim of this study was
to investigate the combined action of miR-34a and miR-15a/16 in non-small cell lung cancer (NSCLC) cells.
Methods: NSCLC cells were transfected with miR-34a and miR-15a/16 mimics and analysed for cell cycle arrest and
apoptosis by flow cytometry. Expression of retinoblastoma and cyclin E1 was manipulated to investigate the role of
these proteins in miRNA-induced cell cycle arrest. Expression of miRNA targets was assessed by real-time PCR. To
investigate if both miRNAs are co-regulated in NSCLC cells, tumour tissue and matched normal lung tissue from 23
patients were collected by laser capture microdissection and compared for the expression of these miRNAs by real-
time PCR.
Results: In the present study, we demonstrate that miR-34a and miR-15a/16 act synergistically to induce cell cycle
arrest in a Rb-dependent manner. In contrast, no synergistic effect of these miRNAs was observed for apoptosis.
The synergistic action on cell cycle arrest was not due to a more efficient down-regulation of targets common to
both miRNAs. However, the synergistic effect was abrogated in cells in which cyclin E1, a target unique to miR-
15a/16, was silenced by RNA interference. Thus, the synergistic effect was due to the fact that in concerted action
both miRNAs are able to down-regulate more targets involved in cell cycle control than each miRNA alone. Both
miRNAs were significantly co-regulated in adenocarcinomas of the lung suggesting a functional link between these
miRNAs.
Conclusions: In concerted action miRNAs are able to potentiate their impact on G1-S progression. Thus the
combination of miRNAs of the same network rather than individual miRNAs should be considered for assessing a
biological response. Since miR-34a and miR-15a/16 are frequently down-regulated in the same tumour tissue,
administrating a combination of both miRNAs may also potentiate their therapeutic impact.
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Background
Lung cancer is the leading cause of cancer-related death
in industrialized countries [1]. Systemic treatment of
lung cancer patients includes chemotherapy, inhibitors
of angiogenesis and inhibitors of EGFR signaling. How-
ever, since the effect of these drugs is only transient, the
overall five-year survival rate is less than 15%. Non-
small cell lung carcinoma (NSCLC) accounts for 80% of
lung cancer and is further subdivided into two major
types, squamous cell carcinoma and adenocarcinoma
[2]. Squamous cell carcinoma usually arises from the
major bronchi, whereas adenocarcinoma arises from dis-
tant airway bronchioles and alveoli. These tumours
show frequent alterations of genes involved in cell cycle
control or apoptosis including k-RAS, EGFR, c-Myc,
cyclin D1 (CCND1), TP53, retinoblastoma (Rb), p16INK
and Bcl2 [3], but the relevant molecular mechanisms
driving the aggressive biological behaviour of these
tumours are largely unknown.
miRNAs are small regulatory RNA molecules at the
post-transcriptional level and are implicated in a wide
variety of biological processes including proliferation,
differentiation and apoptosis [4]. Notably, miRNAs form
networks to regulate the expression of individual com-
ponents of the cell cycle control machinery. Many of
these miRNAs including the let-7 family [5], miR-34 [6],
miR-15a/16 [7], miR-221/222 [8,9], miR-17-92 [10],
miR-107 and miR-185 [11] are frequently dysregulated
in lung cancer and therefore constitute promising tar-
gets for specific anticancer intervention (reviewed by
Negrini et al. [12]).
Many miRNAs are implicated in cell cycle progression
or apoptosis, but surprisingly little information is avail-
able if these miRNAs are able to interact with each
other to co-ordinately regulate these cellular processes.
In addition, it is poorly understood why miRNAs often
share common targets despite the fact that they consti-
tute a relatively small family of RNAs encoded by less
than 1000 genes. In this study we have analysed two
miRNAs, miR-15a/16 and miR-34, which are located at
chromosomal regions 13q14 and 1p34, respectively.
Although these miRNAs contain completely unrelated
seed sequences, they are functionally related since they
are both able to induce G1-G0 cell cycle arrest and
apoptosis [7,13-15]. In addition, they share common tar-
gets including CCND1, CDK4, CDK6, E2F3 and Bcl2.
However, other targets also exist which are unique to
miR-15a/16 (cyclin E1 (CCNE1), cyclin D2 (CCND2) or
cyclin D3 (CCND3)) or miR-34a (c-Myc, n-Myc, and c-
Met) [7,16-18].
To investigate if these miRNAs are able to interact
with each other for the regulation of cellular processes,
they were overexpressed in NSCLC cell lines. Here we
demonstrate that miR-15a/16 and miR-34 act synergisti-
cally to induce cell cycle arrest in a Rb-dependent man-
ner. The synergistic effect can be explained by the fact
that in concerted action, miRNAs are able to down-reg-
ulate more targets than each miRNA alone. Thus, it
may be important to analyse miRNAs in a combinatorial
mode as this may provide additional information on
their role in specific cellular processes. Consistent with
these findings, both miRNAs are frequently down-regu-
lated in adenocarcinomas and squamous cell carcinomas
of the lung. Our results suggest that targeting a combi-
nation of miRNAs involved in the same pathway may
potentiate the therapeutic effect of each individual
miRNA.
Materials and methods
Cell lines and culture conditions
The NSCLC cell lines A549, H2009, H1299 and H358
were obtained from the American Type Culture Collec-
tion, Rockville, MD. All cell lines were cultured in
Iscove’s modified Dulbecco’s medium supplemented
with 2 mM L-alanyl-L-glutamine, 1% penicillin/strepto-
mycin and 5% foetal bovine serum (Sigma) at 37°C and
5% CO2.
Transfection
Cells were seeded in culture flasks 24 h prior to trans-
fection. Co-transfections with plasmid DNA were per-
formed using Effectene reagent (Qiagen), all other
transfections were performed using HiPerFect (Qiagen).
If not otherwise specified, transfection was performed
using 20 nM of hsa-pre-miR-34a, a mixture of 10 nM
hsa-pre-miR-15a and 10 nM hsa-pre-miR-16 or 20 nM
pre-miR miRNA precursor control 1 (Ambion). Si RNAs
against Rb, or CCNE1 (siGENOME SMARTpool, Dhar-
macon) were used at 60 nM or 7.8 nM, respectively.
Control transfections were performed using non-target-
ing Pool 2 (siGENOME). pCMV-Rb [19] or empty con-
trol plasmid were used at 125 ng/ml. Transfection
efficiency of short RNAs and plasmid DNA was moni-
tored using siGloGreen transfection indicator (Dharma-
con) or an RFP-expression plasmid, respectively.
Cell cycle analysis and cell death assay
Cell cycle analysis was performed by flow cytometry
essentially as described [7]. For cell death analysis, float-
ing and adherent cells were harvested, combined,
washed with PBS and stained with 10 μg/ml propidium
idode (Sigma). Apoptotic cells were detected using an
antibody directed against cleaved caspase 3 (clone 5A1E,
1:100, Cell Signaling) as described [20]. Cells were ana-
lysed using an LSR II flow cytometer (BD Biosciences)
and FlowJo 8.8.4 software (Tree Star). As a positive
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control, cells were treated with UV (400 mJ) using a UV
Stratalinker 1800 (Stratagene).
RNA isolation and real-time PCR
Total RNA was extracted from cultured cells using the
miRVana RNA isolation kit according to the manufac-
turer’s instructions (Ambion). TaqMan miRNA assays
(Applied Biosystems) were performed as described [7]
using a Real-Time PCR system 7500 (Applied Biosys-
tems). miRNA levels were normalized to the level
obtained for RNU48. Quantification of Bcl2 was done
using a TaqMan assay (Applied Biosystems); all other
mRNAs were quantified using Quantitec primer assays
(Qiagen). mRNA levels were normalized to the level
obtained for GAPDH. Changes in expression were calcu-
lated using the ΔΔCt method.
Western blot analysis
Western blot analysis was performed as described [7].
Monoclonal antibodies against Rb (clone 3C8, QED
Bioscience) and phospho-Rb (Ser807/811, Cell Signaling)
were diluted 1:1000, monoclonal antibody against Bcl2
(clone 124, Dako) was diluted 1:300, and monoclonal
antibody against a-tubulin (clone B512, Sigma) was
diluted 1:5000. Secondary goat anti-mouse-HRP and
goat anti-rabbit-HRP antibodies (Biorad) were used at
1:5000 or 1:7000, respectively.
Laser capture microdissection
Formalin-fixed paraffin-embedded tissues from 11
adenocarcinomas and 12 squamous cell carcinomas
were used for miRNA expression analysis. Tumour
tissues and corresponding normal tissues from
bronchiolar or alveolar epithelium, respectively, was
collected by laser capture microdissection as described
previously [7]. Stroma components including connec-
tive tissues, inflammatory cells and blood vessels were
excluded. Nucleic acids were subjected to a heat-
treatment in order to remove methylol groups intro-
duced during formalin fixation and subjected to real-
time PCR as described [7]. All experiments using
human specimens were done according to the ethical
guidelines of the Institute of Pathology, University of
Bern, and were reviewed by the institutional review
board.
Statistics
Statistical analyses were performed using the GraphPAD
prism software. Statistical differences were calculated
using unpaired two-tailed student’s t-test. A probability
of p ≤ 0.05 was considered statistically significant. Statis-
tical significance of correlation was assessed by the Pear-
son test.
Results
miR-15a/16 and miR-34a are co-regulated in
adenocarcinomas of the lung
The finding that miR-15a/16 and miR-34a share many
common targets involved in G1 progression prompted
us to analyse if these miRNAs are co-regulated in
NSCLC. Tumour tissues of adenocarcinomas and squa-
mous cell carcinomas and matched normal tissues from
alveolar or bronchial epithelium, respectively, were col-
lected by laser capture microdissection and compared
for the expression of both miRNAs by real-time PCR.
We have shown previously that miR-15a and miR-16
are frequently down-regulated in NSCLC [7]. Here we
demonstrate that the expression of miR-16 is signifi-
cantly correlated to the expression of miR-34a in adeno-
carcinomas (p = 0.018), but not in squamous cell
carcinomas of the lung. Both miRNAs were down-regu-
lated in 82% (9/11), and up-regulated in 18% (2/11) of
adenocarcinomas (Figure 1A). In contrast, miR-34a was
significantly down-regulated in 10/12 squamous cell car-
cinoma samples while miR-16 was down-regulated in 5/
12 tumour samples. Both miRNAs were also signifi-
cantly down-regulated in the NSCLC cell lines A549,
H2009, H1299 and H358 (data not shown).
Co-repression of miRNAs may be due to defects in
miRNA processing. Notably, reduced expression of
Dicer has been detected in NSCLC [21]. To address this
possibility, the same tumour tissues were analysed for
the expression of miR-21, which is frequently up-regu-
lated in lung cancer [22,23]. As shown in Figure 1B,
miR-21 was up-regulated or expressed at normal levels
in 9 of 11 adenocarcinomas and 7 of 12 squamous cell
carcinomas. Thus, abrogation of miRNA processing may
only account for a small subgroup of NSCLC samples.
We next investigated the possibility that both miRNAs
are linked because they are able to mutually regulate
their expression. To this end, miR-15a/16 or miR-34a
were overexpressed by transfection with miRNA precur-
sors (pre-miRNA) in a Rb-deficient NSCLC cell line,
H2009, and analysed for the expression of the miRNA
counterpart. Since H2009 is refractory to cell cycle
arrest induced by miR-15a/16 [7] and miR-34a (see
below), secondary effects on miRNA expression as a
consequence of the G1-G0 arrest can be excluded using
this cell line. However, neither miR-15a/16 nor miR-34a
was able to affect the expression of its counterpart,
while CDK6 mRNA, a target common to both miRNAs,
was significantly down-regulated (Figure 1C).
miR-34a-induced cell cycle arrest depends on the
expression of Rb
One miRNA can affect the expression of hundreds of
proteins [24], which often renders it difficult to identify
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the relevant targets. We have previously shown that
miR-15a/16-induced cell cycle arrest depends on the
expression of Rb. This indicates that components of the
cell cycle machinery upstream of Rb, including cyclin
D1 (CCND1), cyclin D3 (CCND3), CDK4 and CDK6
[7,25,26], are the most relevant targets of miR-15a/16.
To investigate if miR15a/16 and miR-34a share redun-
dant functions, miR-34a was analysed using the same
set of experiments as we have described previously for
miR-15a/16 [7].
To investigate cell cycle arrest, the NSCLC cell lines
A549, H358, H1299 and H2009 were transfected with
pre-miRNA-34a and treated with nocodazole 24 h
post-transfection. Nocodazole traps cells at the G2-M
phase, but ~30% of the transfected A549, H358 or
H1299 cells accumulated in G1-G0 (Figure 2A and 2B)
indicating that miR-34a induces an arrest in this
phase of the cell cycle. In contrast, Rb-deficient
H2009 cells were completely refractory to miR-34a-
induced arrest (Figure 2A and 2B). However, known
targets of miR-34a including CDK4, CDK6, CCND1
and c-Met were significantly down-regulated in these
cells (Figure 2C). Rb reconstitution into Rb-deficient
NSCLC lines restores G1 arrest mechanisms [27]. To
investigate if miR-34a-induced cell cycle arrest
depends on the expression of Rb, the latter gene was
reintroduced into H2009 cells. Co-transfection of
H2009 cells with pre-miR-34a and an empty control
plasmid induced cell cycle arrest in 3.1 ± 1% of the
population (Figure 3A). Consistent with previous find-
ings [27], the percentage of cells in the G1-G0 phase
of the cell cycle increased to 16 ± 1% upon transfec-
tion with a Rb expression plasmid (p = 0.001). This
indicates that Rb per se is able to induce cell cycle
arrest in a significant proportion of the population.
However, Rb plasmid in combination with pre-miR-
Figure 1 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer. (A) miR-16 and miR-34a levels in adenocarcinomas and
squamous cell carcinomas relative to matched normal tissues. (B) miR-21 levels in the same tumour samples, relative to matched normal tissue.
(C) miR-34a and miR-15a/16 are not able to mutually regulate their expression. H2009 cells were transfected with pre-miR-34a (upper panel) or
pre-miR-15a/16 (lower panel) and analysed for the expression of the miRNA counterpart or CDK6 mRNA 42 h post-transfection. Values are relative
to the value obtained for the control transfected with precursor control (n = 3). *, P < 0.05.
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34a induced cell cycle arrest in significantly more cells
(26 ± 1%, p = 0.01) than Rb plasmid in combination
with the precursor control. The expression of Rb pro-
tein was not affected by pre-miR-34a. In contrast,
phospho-Rb was reduced by 50% under these condi-
tions (Figure 3B). In conclusion, the ability of miR-34a
to induce cell cycle arrest depends on the expression
of Rb. Complementary experiments were performed in
A549 cells, in which the Rb gene was knocked down
by RNA interference. The knock-down expressed
three times less Rb protein than the control (Figure
3C). As expected, the knock-down was significantly
more resistant to miR-34a-induced cell cycle arrest
(22 ± 1% in G1-G0) than the control (43 ± 1% in G1-
G0, p < 0.001) (Figure 3D). In conclusion, there is a
significant degree of redundancy between miR-34a
and miR-15a/16 in their ability to induce cell cycle
arrest in NSCLC cells.
miR-15a/16 and miR-34a act synergistically to induce
arrest in G1-G0
We next addressed the question if miR-15a/16 and miR-
34a act together to induce cell cycle arrest. A549 cells
were transfected with increasing concentrations of pre-
miR-15a/16 or pre-miR-34a and analysed for cell cycle
arrest (Figure 4A). From the slope of the dose-response
curves it can be deduced that pre-miR-34a was more
efficient than pre-miR-15a/16 in inducing cell cycle
arrest. We next assessed the concerted action of miR-
15a/16 and miR-34a precursors on cell cycle arrest.
Transfection with 2.5 nM pre-miR-15/16 or transfection
with 0.63 nM pre-miR-34a resulted in a G1-G0 arrest of
A549 cells in 10.9 ± 0.6% and 20.1 ± 1.6% of the popu-
lation, respectively. Interestingly, a mixture with half the
concentrations of pre-miR-15/16 and pre-miR-34a was
more efficient (25.9 ± 2.2%) than each pre-miRNA alone
in inducing a G1-G0 arrest, p ≤ 0.02 (Figure 4A). Consis-
tent results were obtained over a four-fold concentration
range. Thus, these results clearly indicate that miR-15a/
16 and miR-34a act synergistically to induce cell cycle
arrest in G1-G0.
Both pre-miRNAs displayed saturation for cell cycle
arrest at a concentration of 20 nM (data not shown).
Interestingly, a synergistic effect was also obtained at
this concentration: cells transfected with 20 nM pre-
miR-15a/16 or 20 nM pre-miR-34a in each case gave
rise to a G1-G0 arrest in about 37% of the population.
In contrast, co-transfection of cells with both pre-miR-
NAs at half the concentration (10 nM each) resulted in
a G1-G0 arrest in 54.6 ± 2.2% of the population (Figure
4B, 24 h), p < 0.0005. The synergistic effect was
observed 24 h and 48 h post-transfection (Figure 4B).
No synergistic action on cell death
miR-15a/16 and miR-34a are both able to down-regu-
late the anti-apoptotic protein Bcl2 (Figure 5A). In addi-
tion, both miRNAs have been shown to induce
apoptosis in different cell systems [13,15]. We therefore
wondered if these miRNAs also act synergistically to
induce apoptosis. In line with previous findings we were
unable to detect any significant increase in propidium
iodide (PI)-positive A549 or H2009 cells on transfection
with miR-15a/16 (Figure 5B and Additional file 1). Like-
wise, no significant increase in cleaved caspase-3-posi-
tive cells was observed (Figure 5C). In contrast, miR-34a
elicited a 2-3-fold increase in PI-positive cells and an
eight-fold increase in cleaved caspase-3-positive cells 72-
96 h post-transfection (Figure 5B and 5C). Surprisingly,
a mixture of both pre-miRNAs at half the concentration
was less efficient than miR-34a alone in inducing cell
death. In conclusion, no synergism elicited by miR-15a/
16 and miR-34a exists for cell death in NSCLC cells.
Figure 2 H2009 cells are refractory to miR-34a-induced cell
cycle arrest. (A) DNA content distribution of NSCLC cells
transfected with precursor miRNA or precursor control. Cells were
treated for 18 h with nocodazole beginning 24 h post-transfection.
(B) Percent difference in G1-G0 between cells transfected with pre-
miR-34a and cells transfected with precursor control. H2009, A549, n
= 3; H1299 and H358, n = 1. (C) mRNA levels of known miR-34a
targets. H2009 cells were transfected with pre-miR-34a and
harvested 42 h post-transfection (n = 3). Values are relative to the
level obtained for the control transfected with precursor control.
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Combined action of miR-15a/16 and miR-34a on the
stability of individual mRNA targets
We next investigated the mechanism underlying the
synergistic action of miR-34a and miR-15a/16. It is pos-
sible that the observed effect is due to a more efficient
down-regulation of targets common to both miRNAs by
a combined action of miR-34a and miR-15a/16. To
circumvent adverse secondary effects on target gene
expression of individual G1 proteins as a consequence of
cell cycle arrest, the cell line H2009 was again used for
the experiment. Transfection with serial dilutions of
pre-miRNAs allowed the establishment of a direct rela-
tionship between the amount of input pre-miRNA and
the steady-state level of mRNA of the target genes
Figure 3 miR-34a-induced cell cycle arrest depends on the expression of Rb. (A, D), DNA content distribution by flow cytometry of H2009
(A) and A549 cells (D) treated for 18 h with nocodazole beginning 48 h post-transfection. The percent cells in G1-G0 is shown in the upper
panel (n = 3) and a representative histogram of the cell cycle profile is shown in the lower panel. (B, C), Western blot analysis of H2009 (B) and
A549 cells (C) subjected to the same conditions as in (A) and (D) using antibodies directed against Rb or phospho-Rb. Protein levels were
normalised to a-tubulin.
Figure 4 miR-15a/16 and miR-34a act synergistically to induce cell cycle arrest. (A) Cell cycle analysis of A549 cells transfected with pre-
miR-34a and/or pre-miR-15a/16 under non-saturating conditions. Precursors were supplemented with precursor control to yield a total
concentration of 2.5 nM per transfection. *, transfection with 2.5 nM precursor control. Cells were treated for 18 h with nocodazole beginning 24
h post-transfection (n = 3). (B) Cell cycle analysis under saturating conditions. A549 cells were transfected with 20 nM precursor or precursor
control or co-transfected with 10 nM pre-miR-34a and 10 nM pre-miR-15a/16 and treated for 18 h with nocodazole beginning 24 h (left panel) or
48 h (right panel) post-transfection (n = 3).
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CDK4, CDK6 and CCND1, respectively (Figure 6A and
Additional file 2).
Interestingly, transfection of H2009 cells with miR-34a
or miR-15a/16, or co-transfection of H2009 cells with a
mixture of both pre-miRNAs at half the concentration
gave rise to comparable dose-response curves for all the
three target genes (Figure 6A). From these results we
may conclude that miR-15a/16 and miR-34a act in an
additive rather than in a synergistic manner on indivi-
dual mRNAs. Comparable results were obtained in
H2009 and A549 cells excluding the possibility that the
concerted action on individual mRNA targets depends
on the expression of Rb (data not shown).
The synergistic action of miR-15a/16 and miR-34a is due
to the down-regulation of additional genes involved in G1
progression
Although miR-15a/16 and miR-34a share many com-
mon targets, other targets exist which are unique to
miR-15a/16 or miR-34a (Additional file 2). Since no
synergistic effect was observed for individual mRNA tar-
gets, we hypothesized that the observed effect may be
due to the fact that more targets involved in G1-S
progression are repressed by the combined action of
both miRNAs. Target specificity was re-evaluated using
the cell line H2009, which is refractory to miRNA-
induced arrest. In agreement with reports from the lit-
erature [7,16], down-regulation of c-Met mRNA was
specific for miR-34a, whereas down-regulation of
CCND3 and CCNE1 mRNAs were specific for miR-15a/
16 (Figure 6B and Additional file 2). In contrast, CCNE2
mRNA, which contains a target site for miR-34a [16],
and CCNA1 mRNA, which contains no target site, were
virtually unaffected.
To address the possibility that the synergistic effect was
due to an increased number of targets, CCNE1, a target
unique to miR-15a/16 (Figure 6B and Additional file 2),
was knocked down in A549 cells by RNA interference
resulting in 80.3 ± 6.6% less CCNE1 mRNA. We would
expect that the synergistic effect would be reduced under
these conditions, given that one of the unique targets,
CCNE1, has been removed. This was indeed the case. The
percentage of cells in the G1-G0 phase increased to 36% on
co-transfection with CCNE1 siRNA and pre-miR-control
(Figure 7A, striped columns). However, CCNE1 siRNA had
only a low impact on cell cycle arrest of cells
Figure 5 No synergism on cell death. (A) Bcl2 expression. A549 or H2009 cells were transfected with 20 nM precursors and harvested 42 h
post-transfection. Western blot analysis was performed using a monoclonal antibody against Bcl2. Protein levels were normalized to a-tubulin
and presented relative to the level obtained for the control. (B) Time-course of propidium iodide (PI)-positive A549 and H2009 cells by flow
cytometry. Cells were transfected with concentrations of precursors as indicated in the legend to Fig. 4B (n = 3). Cells were gated as shown in
Additional file 1A. (C) Cleaved caspase-3-positive cells. H2009 cells were analysed for the presence of cleaved caspase 3 by flow cytometry 72 h
post-transfection (n = 3). Values are relative to the level obtained for the control transfected with precursor control. As a positive control, cells
were treated with UV.
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overexpressing miR-15a/16 (Figure 7A, white columns),
which can be explained by the fact that CCNE1 was already
down-regulated by miR-15a/16. In contrast, the percentage
of A549 cells in G1-G0 increased almost two-fold on co-
transfection with pre-miR-34a and CCNE1 siRNA relative
to cells co-transfected with pre-miR-34a and si control
(Figure 7A, grey columns), suggesting that CCNE1 siRNA
and pre-miR-34a act together to induce cell cycle arrest in
a more efficient manner. Notably, CCNE1 siRNA in combi-
nation with pre-miR-34a (59.0 ± 3.1%; grey column) and
CCNE1 siRNA in combination with both pre-miRNAs
(61.6 ± 5.3%; black column; p = 0.5) induced a G1-G0 arrest
with the same efficiency. Thus, the synergistic effect
exerted by the combined action of miR-15a/16 and miR-
34a was clearly abrogated. In contrast, si control in combi-
nation with both pre-miRNAs together gave rise to almost
two times more cells in G1-G0 than si control in combina-
tion with pre-miR-34a or pre-miR-15a/16, respectively (p <
0.004). The observed effects were not cell-line-specific,
since comparable results were obtained for A549 (Figure
7A) and H1299 cells (Figure 7B). In conclusion, the syner-
gistic effect of miR-15a/16 and miR-34a is due to the fact
that more miRNA targets are down-regulated by the com-
bined action of both miRNAs.
Discussion
Cell cycle progression critically depends on numerous
regulatory processes which are often deregulated in
Figure 6 Concerted action of miR-15a/16 and miR-34a on
individual mRNA targets. (A) mRNA levels of targets common to
both miRNAs. H2009 cells were transfected with pre-miR-15a/16 or
pre-miR-34a alone or co-transfected with both pre-miRNAs together
(pre-miR-mix) at concentrations as indicated in the figure. (B)
Expression level of targets unique to miR-15a/16 or miR-34a. Analysis
was performed as described in the legend to Fig. 2C (n = 3). *, p <
0.05.
Figure 7 Synergistic action on cell cycle arrest is due to the
down-regulation of unique mRNA targets. A549 (A) or H1299
cells (B) were co-transfected with 20 nM miRNA precursors and 7.8
nM siRNA against CCNE1 and subsequently treated for 18 h with
nocodazole beginning 24 h post-transfection. Comparable results
were also obtained 48 h post-transfection (data not shown).
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cancer (reviewed by Evan et al. [28]). miRNAs contri-
bute to the complexity of cell cycle control by interfer-
ing with a variety of different components of the cell
cycle machinery allowing the coordinated regulation of
gene expression at the post-transcriptional level
(reviewed by Bueno et al. [29] and Carleton et al. [30]).
miR-15a/16 and miR-34a share overlapping functions.
They both induce cell cycle arrest in G1-G0 and share
common targets including CCND1, CDK4 and CDK6. In
addition, the ability of either one of these miRNAs to
induce cell cycle arrest in G1-G0 largely depends on the
expression of Rb (Figure 3 and ref. [7]). Cyclin D in
complexes with CDK4 or CDK6, and cyclin E in a com-
plex with CDK2 regulate progression through the G1-S
boundary of the cell cycle. These complexes phosphory-
late and thereby prevent Rb from binding to E2F, which
on release, drives cells from G1 to S phase (reviewed by
Morgan et al. [31]). From these results we may conclude
that functionally relevant targets of either type of
miRNA must be upstream of Rb. These include CCNE1
and CCND3, which are unique to miR-15a/16, c-Myc
and c-Met, which are unique to miR-34a and CCND1,
CDK4 and CDK6, which are common to both miRNAs.
With the exception of CDK4 and c-Myc, all these genes
are confirmed targets of miR-15a/16 and miR-34a in
NSCLC cells [7,14,16,26]. In contrast, experimentally
validated targets downstream of Rb including E2F1,
E2F2, E2F3, E2F7, WEE1, CHK1 and CARD10
[25,32,33] seem to be less relevant for the regulation of
cell cycle progression by miR-15a/16 or miR-34a, at
least in NSCLC cells.
The finding that both miRNAs share highly related func-
tions is further illustrated by the fact that both miRNAs
are co-regulated in all adenocarcinoma samples. In the
majority of NSCLC cases, both miRNAs are significantly
down-regulated indicating that they play an important role
as tumour suppressor. Tumours can escape the concerted
action of miR-15a/16 and miR-34a by down-regulation of
both miRNAs or, alternatively, by down-regulation of Rb.
Mechanisms which may lead to dysregulation of miR-15a/
16 or miR-34a in cancer include deletion of the respective
miRNA loci [7,34], defects in miRNA processing [21],
altered promoter methylation [35], or altered expression
of transcriptional regulators [36-38]. Defects in miRNA
processing may account for only a subgroup of NSCLC,
since the majority of tumours either expressed normal or
high levels of miR-21. p53 is a potent transactivator of
miR-34a [39,40], and is implicated in the processing of
miR-16 [40]. However, no correlation was observed
between the mutation status of p53 and the expression
level of miR-34a [6] or miR-15a/16 [41]. In addition, the
possibility that both miRNAs are able to mutually regulate
their expression can be excluded (Figure 1C). Thus, it
rather seems that several independent mechanisms may
account for the dysregulation of miR-15a/16 and miR-34a
in NSCLC.
Why is there a relatively high degree of redundancy
between miRNAs? To address this question we co-trans-
fected cells with miR-15a/16 and miR-34a and demon-
strated that both miRNAs act synergistically to induce
cell cycle arrest in G1-G0. In contrast, the concerted
action of these miRNAs on common mRNA targets was
additive rather than synergistic. Thus, there seems to be
little interference in binding of these miRNAs to the
same target molecule and each miRNA contributes to
the mRNA stability in an independent manner. The
synergistic effect can rather be explained by the fact that
in addition to their targets common to both miRNAs
they are also able to bind to targets unique to either type
of miRNA. Thus, in a combinatorial mode, both miRNAs
are able to down-regulate more targets than each miRNA
alone. This is based on the finding that knocking down
CCNE1, a target unique to miR-15a/16, by RNA interfer-
ence, abrogated the synergistic effect exerted by the com-
bination of both miRNAs (Figure 7). These effects were
not cell-line-specific, since comparable results were
obtained with A549 and H1299 cells. This model is in
agreement with our results that miR-34a and miR-15a/
16 acted synergistically under both saturating and non-
saturating conditions. In contrast, if the synergistic effect
of these miRNAs were due to a more efficient repression
of individual targets, we would expect such an effect to
occur only under non-saturating conditions. miRNAs
exert fine-tuning regulatory functions, in most cases lead-
ing only to a modest repression of target mRNAs and
proteins [24]. Our results suggest that miRNAs can
potentiate their impact on the regulation of cellular pro-
cesses by acting in a combinatorial mode.
Surprisingly, we were unable to detect any synergistic
effect on apoptosis. Although both miRNAs are able to
target Bcl2, only miR-34a was able to induce apoptosis.
This may be due to quantitative differences in their abil-
ity to down-regulate Bcl2. Alternatively, other anti-apop-
totic genes besides Bcl2, which are targeted by miR-34a,
but not miR-15a/16, may have to be down-regulated in
order apoptosis can occur. It is noteworthy, however,
that the observed effects may depend on the cell system
as miR-15a/16 was able to induce apoptosis in CLL [15].
There are only few examples of miRNAs in the literature
that act in a synergistic manner. Ivanosvska and Cleary
were the first to investigate the concerted action of miR-
16 and miR-34a on cell cycle arrest. However, based on
their results it was not clear if both miRNAs acted in an
additive or synergistic manner [42]. miR-84 and let-7 pro-
mote terminal differentiation of the hypodermis and cessa-
tion of molting in C. elegans in a synergistic manner [43].
However, miR-84 and let-7 share identical seed sequences,
suggesting that they regulate the same set of target genes.
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In addition, pairs of a cytomegalovirus derived miRNA
and a host cell derived miRNA acted on the same gene
(MICB) through site proximity in a synergistic manner
[44]. Thus different mechanisms may exist that may lead
to a synergistic action of miRNAs.
Therapeutic strategies for the treatment of human
cancer based on modulation of miRNA activity in can-
cer tissues have gained much attention in the past few
years [12,45-49]. In a recent publication, a new formula-
tion is described that allows the reintroduction of miR-
NAs, depleted in cancer cells, in order to reactivate
cellular pathways that drive a therapeutic response [50].
The authors demonstrated that formulated miR-34a
blocked tumour growth in a mouse model of NSCLC.
Our results suggest that administering formulated miR-
34a in combination with formulated miR-15a/16 may
lead to a significant increase in the therapeutic impact.
This strategy may be particularly effective for the treat-
ment of NSCLC, since both types of miRNAs are nor-
mally down-regulated in this class of tumours.
Conclusion
It is generally agreed that miRNAs form part of net-
works to control cellular processes. Currently, the
miRNA field is focused primarily on the identification of
novel targets of individual miRNAs, but little informa-
tion is available how miRNAs act in a combinatorial
mode. We show that miR-34a and miR-15a/16 act
together to control cell cycle progression in a synergistic
and Rb-dependent manner. From these results we may
conclude that the combination of miRNAs, which form
part of the same network, rather than individual miR-
NAs should be considered for assessing a biological
response. In addition, our study may have translational
implications. Since both miRNAs are significantly down-
regulated in the majority of adenocarcinomas, adminis-
tering a combination of both miRNAs may potentiate
the therapeutic impact of each individual miRNA.
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Additional file 1: Analysis of propidium iodide (PI)-stained cells by
flow cytometry. H2009 and A549 cells were transfected as described in
the legends to Figure 5 and analysed 72 h or 96 h post-transfection,
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experimentally validated targets and CDK6 and c-MYC are predicted
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